CITIUS ONCOLOGY INC
For the period ended Sep 30, 2024. Filed Dec 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Dec 27, 2024
CTOR$0.52-5.9%Stored close · as of Nov 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
Checking your notes…
| Exhibit Number | Description of Document | Registrant’s Form | Dated | Exhibit Number | Filed Herewith |
|---|---|---|---|---|---|
| 2.1* | Agreement and Plan of Merger and Reorganization, dated as of October 23, 2023, by and among Citius Pharmaceuticals, Inc., Citius Oncology, Inc., TenX Keane Acquisition and TenX Merger Sub, Inc. | 8-K | 10/24/2023 | 2.1 | |
| 3.1 | Certificate of Incorporation of Citius Oncology, Inc. | 8-K | 08/16/2024 | 3.1 | |
| 3.2 | Bylaws of Citius Oncology, Inc. | 8-K | 08/16/2024 | 3.2 | |
| 4.1 | Specimen Common Stock Certificate of Citius Oncology, Inc. | S-4 | 07/11/2024 | 4.5 | |
| 4.2 | Description of Common Stock. | X | |||
| 10.1 | Amended and Restated Registration Rights Agreement, dated as of August 12, 2024 by and between Citius Oncology, Inc. and the signatories thereto. | 8-K | 08/16/2024 | 10.1 | |
| 10.2 | Amended and Restated Shared Services Agreement, dated as of August 12, 2024, by and among Citius Oncology, Inc. and Citius Pharmaceuticals, Inc. | 8-K | 08/16/2024 | 10.2 | |
| 10.3† | 2023 Omnibus Stock Incentive Plan. | X | |||
| 10.4† | 2024 Omnibus Stock Incentive Plan. | 8-K | 8/5/2024 | 10.5 | |
| 10.5* | Asset Purchase Agreement, dated as of September 1, 2021, between Dr. Reddy’s Laboratories S.A. and Citius Pharmaceuticals, Inc. | S-4 | 11/13/2023 | 10.15 | |
| 10.6* | Amended and Restated License, Development and Commercialization Agreement, dated as of February 26, 2018, between Eisai, Ltd. and Dr. Reddy’s Laboratories S.A. | S-4 | 11/13/2023 | 10.16 | |
| 10.7* | Amendment No. 1 to Amended and Restated License, Development and Commercialization Agreement, dated as of August 9, 2018, between Eisai, Ltd. and Dr. Reddy’s Laboratories S.A. | S-4 | 11/13/2023 | 10.17 | |
| 10.8* | Amendment No. 2 to Amended and Restated License, Development and Commercialization Agreement, dated as of August 31, 2021, between Eisai, Ltd. and Dr. Reddy’s Laboratories S.A. | S-4 | 11/13/2023 | 10.18 | |
| Exhibit Number | Description of Document | Registrant’s Form | Dated | Exhibit Number | Filed Herewith |
|---|---|---|---|---|---|
| 10.9 | Side Letter Agreement, dated August 12, 2024, by and by and among Citius Pharmaceuticals, Inc., Citius Oncology, Inc., TenX Keane Acquisition and TenX Merger Sub, Inc. | 8-K | 08/16/2024 | 10.8 | |
| 10.10 | Promissory Note, dated July 18, 2023, issued by TenX Keane Acquisition to 10XYZ Holdings LP. | 8-K | 07/18/2023 | 10.1 | |
| 10.11 | Promissory Note, dated October 18, 2023, issued by TenX Keane Acquisition to 10XYZ Holdings LP. | 8-K | 10/18/2023 | 10.1 | |
| 10.12 | Promissory Note, dated August 16, 2024, by and between Citius Oncology, Inc. and Citius Pharmaceuticals, Inc. | 8-K | 08/16/2024 | 10.9 | |
| 16.1 | Letter from Marcum LLP to the Securities and Exchange Commission, dated August 16, 2024. | 8-K | 08/16/2024 | 16.1 | |
| 19.1 | Insider Trading Policy. | -- | -- | -- | X |
| 31.1 | Certification of the Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a). | -- | -- | -- | X |
| 31.2 | Certification of the Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a). | -- | -- | -- | X |
| 32.1 | Certifications of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002. | -- | -- | -- | X |
| EX-101.INS | INLINE XBRL INSTANCE DOCUMENT | -- | -- | -- | X |
| EX-101.SCH | INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | -- | -- | -- | X |
| EX-101.CAL | INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE | ||||
| EX-101.DEF | INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE | -- | -- | -- | X |
| EX-101.LAB | INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE | -- | -- | -- | X |
| EX-101.PRE | INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE | -- | -- | -- | X |
| 104 | Cover Page Interactive Data File, formed in Inline Extensible Business Reporting Language (iXBRL) | -- | -- | -- | X |
| * | Certain portions, schedules and exhibits to this Exhibit have been omitted pursuant to Item 601(a)(5) or Item 601(b)(10)(iv), as applicable, of Regulation S-K. The Registrant agrees to furnish supplemental copies of all omitted portions, exhibits and schedules to the Securities and Exchange Commission upon its request. |
| † | Indicates management contract or compensatory plan. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.